- Home
- ADPT vs COMM Comparison
ADPT vs COMM Comparison
Compare ADPT & COMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- COMM
- Stock Information
- Founded
- ADPT 2009
- COMM 1976
- Country
- ADPT United States
- COMM United States
- Employees
- ADPT N/A
- COMM N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- COMM Radio And Television Broadcasting And Communications Equipment
- Sector
- ADPT Health Care
- COMM Technology
- Exchange
- ADPT Nasdaq
- COMM Nasdaq
- Market Cap
- ADPT 1.1B
- COMM 1.1B
- IPO Year
- ADPT 2019
- COMM 2013
- Fundamental
- Price
- ADPT $9.03
- COMM $4.82
- Analyst Decision
- ADPT Buy
- COMM Hold
- Analyst Count
- ADPT 6
- COMM 4
- Target Price
- ADPT $9.83
- COMM $3.50
- AVG Volume (30 Days)
- ADPT 3.0M
- COMM 5.0M
- Earning Date
- ADPT 05-01-2025
- COMM 05-01-2025
- Dividend Yield
- ADPT N/A
- COMM N/A
- EPS Growth
- ADPT N/A
- COMM N/A
- EPS
- ADPT N/A
- COMM 3.42
- Revenue
- ADPT $189,527,000.00
- COMM $4,417,100,000.00
- Revenue This Year
- ADPT $21.20
- COMM $21.62
- Revenue Next Year
- ADPT $21.99
- COMM $8.19
- P/E Ratio
- ADPT N/A
- COMM $1.40
- Revenue Growth
- ADPT 8.61
- COMM 16.19
- 52 Week Low
- ADPT $2.99
- COMM $0.86
- 52 Week High
- ADPT $10.28
- COMM $7.19
- Technical
- Relative Strength Index (RSI)
- ADPT 57.82
- COMM 59.61
- Support Level
- ADPT $8.38
- COMM $4.54
- Resistance Level
- ADPT $9.51
- COMM $5.07
- Average True Range (ATR)
- ADPT 0.66
- COMM 0.27
- MACD
- ADPT 0.16
- COMM 0.18
- Stochastic Oscillator
- ADPT 63.02
- COMM 87.18
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. They have operating segments, which excludes our Home segment: Connectivity and Cable Solutions (CCS), Outdoor Wireless Networks (OWN), Networking, Intelligent Cellular and Security Solutions (NICS) and Access Network Solutions (ANS).